5/24/2007

New data shows AstraZeneca's combination asthma treatment Symbicort improved quality of life and satisfaction for patients better than the drug's two main ingredients do separately. Symbicort, recently approved for long-term use, is a combination of the inhaled corticosteroid budesonide and the beta agonist formoterol fumarate dehydrate.

Full Story:
Forbes

Related Summaries